Panobinostat (LBH589)

For research use only. Not for use in humans.

製品コードS1030 別名:NVP-LBH589

Panobinostat (LBH589)化学構造

分子量(MW):349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.

サイズ 価格(税別) 在庫  
JPY 16900 あり
JPY 46800 あり
JPY 113200 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(236)

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
ターゲット
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
体外試験

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 NEn0XZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHoNE0yOCEQvF2= M4\NelAuPCCm NH74T2VqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M3;tbFI3PzB{N{i0
HepG2 M1[xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LNeFAuOTBizszN Mn;wNE01KGR? NUTONpVVcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFvOcFIzPjdyMke4OC=>
HT29 NFXTeXZHfW6ldHnvckBCe3OjeR?= NWXTUlZ[PTEEoH7N MljqNlQuPzJiaB?= MnixbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4UhOyCjZoTldkA1QMLiaNMg NYPRRopmOjZ5MEK3PFQ>
HepG2 NXzBOHFMTnWwY4Tpc44hSXO|YYm= M4TOflUxyqCwTR?= MnW1NlQuPzJiaB?= M2LQfYlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhOjUEoHlCpC=> M3zzSFI3PzB{N{i0
HCC827 NXjYWpltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXEflQ2NzdwNT:xNEBvVQ>? NFPXVZU4OsLiaB?= NHyzb4lFVVOR MWHlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? M2\USVI3Pjd3NEi0
A549  NGrleIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoX4NVAwOTVxMkCgcm0> M3:wWFczyqCq MnTxSG1UVw>? M4r1W4VvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk MV[yOlY4PTR6NB?=
NCI-H460  NFG5VYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfENVAwOjBxM{Cgcm0> NXLxbYZ3PzMEoHi= NGL4RYVFVVOR MXPlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? NET6TVMzPjZ5NUS4OC=>
J89GFP MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTkVoN4TE2VT9Mg NYXTeJlMTUN3ME20PU45PSEEsTCxNk43PSCwTR?= NH7XRlgzPjV4M{W2PC=>
THP89GFP MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\YSG1UV8Li Mm\VSWM2OD1zOT6zOEDDuSB4LkSzJI5O NVTTTW8yOjZ3NkO1Olg>
SK-NEP-1 NIXqNWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjiS3llOC5yMfMAl|ExNjBizszN M4jpfFI1KGh? Mn[2SG1UV8Li NWPFN|R3UUN3ME23Ok4{PCCwTR?= M2HpR|I3OTd4MkG5
G401 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXmwMlAy6oDVMUCuNEDPxE1? Mnv3NlQhcA>? MYnEUXNQyqB? NX\Jeol{UUN3ME2xOFMvODJibl2= NHnyfGIzPjF5NkKxPS=>
SK-NEP-1 M1\6dmNmdGxiVnnhZoltcXS7IFHzd4F6 MnHVOVAhdk1? NFHnTIsy6oDVNDDk NUmzV3VUTE2VT9Mg M2\qTpJm\HWlZYOgZ4VtdCC|dYL2bZZidCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? M3XQZlI3OTd4MkG5
G401 M2XYXGNmdGxiVnnhZoltcXS7IFHzd4F6 M1rVNFUxKG6P MnjxNgKBmzRiZB?= MlHKSG1UV8Li NXL1Z5hNemWmdXPld{Bk\WyuIIP1dpZqfmGuIHnuJIEhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ MYmyOlE4PjJzOR?=
SK-NEP-1 NYTvZm9ISXCxcITvd4l{KEG|c3H5 M1fyd|UxNzFyMDDuUS=> NIXDZnczPCCq M4[xdGROW00EoB?= MXvpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NViyeFc5OjZzN{[yNVk>
G401 MVrBdI9xfG:|aYOgRZN{[Xl? M{HnVVUxNzFyMDDuUS=> NFj1SlQzPCCq Mk\ySG1UV8Li MoX3bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NFXNUpczPjF5NkKxPS=>
SK-NEP-1 NE[5R3VHfW6ldHnvckBCe3OjeR?= M3;FT|UxNzFyMDDuUS=> Mk\mNlQhcA>? MXHEUXNQyqB? NI\KWWp{cG:5czD0bIUhcW6mdXP0bY9vKG:oIFTORUBnemGpbXXueIF1cW:w MXiyOlE4PjJzOR?=
G401 NVP4N5RNTnWwY4Tpc44hSXO|YYm= NHLKNlM2OC9zMECgcm0> NITXWo0zPCCq Ml[5SG1UV8Li NX3O[4Vme2ixd4OgeIhmKGmwZIXjeIlwdiCxZjDEUmEh\nKjZ33lcpRifGmxbh?= MWiyOlE4PjJzOR?=
SK-NEP-1 MnHvSpVv[3Srb36gRZN{[Xl? M3jzeVUxNzFyMDDuUS=> MkHuNlQhcA>? M3;4UmROW00EoB?= NFK0dHJqdmS3Y3XzJINmdGxiY4njcIUh\Gm|b4Lk[ZLDqA>? NWHDZYk5OjZzN{[yNVk>
G401 NWrUNJM6TnWwY4Tpc44hSXO|YYm= NWf4VHA1PTBxMUCwJI5O M1WxV|I1KGh? MoPvSG1UV8Li M2DVXIlv\HWlZYOgZ4VtdCCleXPs[UBlcXOxcnTlduKh NV3ye5Z3OjZzN{[yNVk>
RPMI 8226 Mo\uR4VtdCCVdYL2bZZidCCDc4PhfS=> NFPPRoYzNzRxNjDuUS=> MVi0PQKBkWh? M{nseYlv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? NXXJXmZVOjZyMECyPVI>
OPM2 MmHLR4VtdCCVdYL2bZZidCCDc4PhfS=> MmjwNk81NzZibl2= NF;Ncpg1QOLCiXi= NHm1d2hqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq NIK4fJozPjByMEK5Ni=>
U266 M1XkbWNmdGxiU4Xyeol3[WxiQYPzZZk> NH;JZ|MzNzRxNjDuUS=> MVK0PQKBkWh? Moe5bY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? NUfKN3htOjZyMECyPVI>
H929 NWPUbpBoS2WubDDTeZJ3cX[jbDDBd5NigQ>? MkXVNk81NzZibl2= MWK0PQKBkWh? NX;LcIxpcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= NUPW[ZdOOjZyMECyPVI>
RPMI 8226  NFHrNJhCeG:ydH;zbZMhSXO|YYm= MX[05qCKdk1? MlHrNlQwPDhiaB?= NH\2bIdqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MnfqNlYxODB{OUK=
HCC827 NWHw[VNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml21NVAhdk1? NX:2cZY6PDhiaB?= M3KzdGROW09? M1HRdYVvcGGwY3XzJINqe3CuYYTpckB{\W6|aYTpeol1gcLi NFSzWmkzPTl2NE[xOy=>
NCI-H23 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVixNEBvVQ>? M1LkeVQ5KGh? NIf2dY5FVVOR NXPLRWJC\W6qYX7j[ZMh[2m|cHzheIlvKHOnboPpeIl3cXS7wrC= Mn7XNlU6PDR4MUe=
AML3 NIi4blFHfW6ldHnvckBCe3OjeR?= NUXBWVFGOC1zIN88US=> NXvXRnVXOjUEoHi= NFfkRnZqdmS3Y3XzJGRPSSCocnHncYVvfGG2aX;uxsBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NX3oO|ZYOjV4MUK5OFE>
ML-1 M4\6dmZ2dmO2aX;uJGF{e2G7 Mn\nNE0yKM7:TR?= M1;0eFI1yqCq M3iycIlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NIXJOI8zPTZzMkm0NS=>
RPMI-8226vr10  NWDXbYltTnWwY4Tpc44hSXO|YYm= NIqwVWExNTFizszN NXvqWlVqOjUEoHi= NUnXZpZFcW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MlL4NlU3OTJ7NEG=
ML-1 M2X3dWZ2dmO2aX;uJGF{e2G7 NVPYWlhOOSEQvF2= MVKyOOKhcA>? NYXJc4pYcW6lcnXhd4V{KGOjc4Dhd4UuOyCjY4Tpeol1gSB2LX\vcIQ> NGP6NlUzPTZzMkm0NS=>
RPMI-8226vr10  M4ewR2Z2dmO2aX;uJGF{e2G7 M{XsRVEh|ryP MnfXNlTDqGh? MmfqbY5kemWjc3XzJINie3Cjc3WtN{Bi[3Srdnn0fUAzNjVvZn;s[C=> MYeyOVYyOjl2MR?=
SK-N-BE (2) NGLwU4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1v4Z|I16oDLaB?= MVvJR|UxRTFyND6w5qCKyrIkgJm3Mlghdk1? M2jzW|I2OzB6OUG2
SK-N-BE (2), PAN  MK NXLLNWVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[yOQKBkWh? M1XKeGlEPTB;MUC0MlDjiIoEsfMAjVcvQCCwTR?= MVWyOVMxQDlzNh?=
SK-N-BE (2), MK  PAN M2WwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4r2W|I16oDLaB?= NGDsNoNKSzVyPUO4Nk4x6oDLwsJihKk1Oy5{IH7N MXuyOVMxQDlzNh?=
SK-N-AS MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHxNlTjiImq MVTJR|UxRTN5LkJihKnDueLCiUKuOEBvVQ>? M2HERVI2OzB6OUG2
SK-N-DZ NWXHeWZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFO3d2YzPOLCiXi= NEPsd3NKSzVyPUG3MlHjiIoEsfMAjVAvPCCwTR?= MnOwNlU{ODh7MU[=
Caki-1 MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TDZVExNzJ3L{WwJI5O NWfYZZhwPDhiaB?= NGLk[ZBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= M4HUZVI2Ojd7MUmx
ACHN MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzEOnEyOC9{NT:1NEBvVQ>? NHLoRXM1QCCq NU\JSmx7cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny MoPSNlUzPzlzOUG=
769-P NUTifpZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInk[GIyOC9{NT:1NEBvVQ>? NUDOdGZDPDhiaB?= M1fpZ4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= MYCyOVI4QTF7MR?=
786-O  MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O4d|ExNzJ3L{WwJI5O NEH0SXQ1QCCq M{L1TIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= NI\Jd3YzPTJ5OUG5NS=>
Caki-1 MXHBdI9xfG:|aYOgRZN{[Xl? M1rDelUxKG6P M{PSZlQ5KGh? MUfpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? NXz5OZF{OjV{N{mxPVE>
ACHN MkHDRZBweHSxc3nzJGF{e2G7 MXu1NEBvVQ>? NVHrWpA1PDhiaB?= NEHPZ2ZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= MnLHNlUzPzlzOUG=
769-P MVXBdI9xfG:|aYOgRZN{[Xl? NV;QXHRTPTBibl2= Mle2OFghcA>? NFjPcI9qdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= NWXtSoE{OjV{N{mxPVE>
786-O  NGrVdI1CeG:ydH;zbZMhSXO|YYm= MknqOVAhdk1? MX20PEBp Mn6wbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? NV\URo5VOjV{N{mxPVE>
Caki-1 M4G3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUmyOU82OCCwTR?= MUS0PEBp M{D0TGROW09? MX7pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk MlX6NlUyPzZ|NUS=
ACHN M4fCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnW[HIzPS93MDDuUS=> Mn\JOFghcA>? NE\Fd4ZFVVOR MoH6bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?= MWeyOVE4PjN3NB?=
769-P MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PH[|I2NzVyIH7N NHL4coY1QCCq NHLFUVFFVVOR M2n1VIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK= NHnDNWYzPTF5NkO1OC=>
Caki-1 NVnrTI5mS2:ub375JGZwem2jdHnvckBCe3OjeR?= MYq1NEBvVQ>? MkK4O{0yPCCm NGnIVpBFVVOR NFP0dmF{fXCycnXzd4VlKGOxbH;ufUBnd3KvYYTpc44he2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKHerdHigZo9zfGW8b33pZkDDqA>? NW\jd4pxOjVzN{[zOVQ>
ACHN NWrGPYw3S2:ub375JGZwem2jdHnvckBCe3OjeR?= MlPlOVAhdk1? NYPUN4I2Py1zNDDk NYLW[XZ[TE2VTx?= NX\yNJJSe3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB? M4DUeVI2OTd4M{W0
769-P NHLWVJZEd2yxbomgSo9zdWG2aX;uJGF{e2G7 MXe1NEBvVQ>? MXW3MVE1KGR? NV2zUFRjTE2VTx?= NUjq[mJle3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB? Mk\HNlUyPzZ|NUS=
Caki-1 NHzQe4dCeG:ydH;zbZMhSXO|YYm= NIToN2o2OCCwTR?= NXT5dYpSPDhiaB?= MVXEUXNQ M162OIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NWLrXWs{OjVzN{[zOVQ>
ACHN M{TTfGFxd3C2b4Ppd{BCe3OjeR?= MWW1NEBvVQ>? MYW0PEBp NITTfm5FVVOR NYjuT4c2cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NHLWNIMzPTF5NkO1OC=>
769-P Mk\QRZBweHSxc3nzJGF{e2G7 MVW1NEBvVQ>? NEjpWnE1QCCq NVP6c|dHTE2VTx?= M1[3R4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NU\Jfo1qOjVzN{[zOVQ>
MDA-MB-231 MWHNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk> NYHTWFBwOTEEoH7N MYqzxsBl MX7EUXNQ NWDDRVZw[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg MUWyOFgyODR7Nx?=
BT-549 NWDjT4ZvVW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7 MnrBNVDDqG6P MWKzxsBl NHLBWIZFVVOR M{nMPYFtfGW{czDj[YxtKG2xcoDoc4xw\3oEoB?= M1nDdFI1QDFyNEm3
MCF-7  NUPrd2RqVW:{cHjvcI9ocWOjbDDDdpl{fGGuIG\pc4xmfCBqQ2[pJGF{e2G7 NHy4WIwyOMLibl2= NHzZc4I{yqCm MUfEUXNQ NWjWZW1Y[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg M3fIclI1QDFyNEm3
MCF-7 M3TlcGZ2dmO2aX;uJGF{e2G7 Mm\qOU02OCCwTR?= M1HmTFI1KGh? MUHEUXNQ M4XZeZJm\HWlZXSgeIhmKGyndnXsJI9nKGW6cILld5Nqd25ib3[gSXLPuSxiUGKgZY5lKE[xeFGxxsA> MXyyOFM3PjRyNx?=
CTS M1raWWFxd3C2b4Ppd{BCe3OjeR?= NF\RNpYx6oDVNECgcm3DqA>? NFT4XJg1QCCq NWjHc4JCcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Ml[wNlQzPDR2Mkm=
OCI-AML3  NXnt[np5SXCxcITvd4l{KEG|c3H5 NFPmNGgx6oDVNECgcm3DqA>? NVi5PVV4PDhiaB?= MlLZbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NV;6ZpFxOjR{NES0Nlk>
U937 M{PSN2Fxd3C2b4Ppd{BCe3OjeR?= MmDQNQKBmzRyIH7NxsA> NUjXNJdkPDhiaB?= MXPpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWSxd2lIOjR{NES0Nlk>
PC3 MkXXRZBweHSxc3nzJGF{e2G7 NF\wNVAxNTFyMDDuUS=> M4HVPFI1NzR6IHi= NFvrN2VqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NX\oeHdxOjRzNkOyN|A>
PC3-AR Mnn4RZBweHSxc3nzJGF{e2G7 M2XLRlAuOTByIH7N M1q2XVI1NzR6IHi= NYr5NJR[cW6mdXPld{BieG:ydH;zbZMhcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NUHPXm91OjRzNkOyN|A>
PC3 MkjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTnNE0yODBibl2= MXWyOE81QCCq NWnYUoNycW6mdXPld{Bi[2O3bYXsZZRqd25ib3[gd5VjTzFicH;weYxifGmxbh?= NHHMemozPDF4M{KzNC=>
PC3-AR NGjFOnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3SV3lsOC1zMECgcm0> M{PsNFI1NzR6IHi= NHvMU|dqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKHSqZTDHNm0heGijc3W= NGH3fXkzPDF4M{KzNC=>
PC3 M4HZO2Z2dmO2aX;uJGF{e2G7 MnnoNE0yODBibl2= NEjsUFEzPCCq M3jPcZN2eHC{ZYPz[ZMh\XiycnXzd4lwdiCxZjDhZ5RqfmG2ZXSgRXRONCCDa4SgZY5lKEW{a{GvNkBxem:2ZXnu NHnVVFYzPDF4M{KzNC=>
PC3-AR MVzGeY5kfGmxbjDBd5NigQ>? NH;pN2wxNTFyMDDuUS=> MmfZNlQhcA>? MnXLd5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIHHjeIl3[XSnZDDBWG0tKEGtdDDhcoQhTXKtMT:yJJBzd3SnaX6= NIS0dY8zPDF4M{KzNC=>
OS-RC-2 NYn2XJJSS2WubDDWbYFjcWyrdImgRZN{[Xl? NVjo[JB1OC1zMECwJI5O NXTlZZl5OjRxNEivO|IhcA>? M3;s[2ROW09? MkT1[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NVv4[pNLOjRzNES3N|c>
OS-RC-2 M2fFcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHHN2JyPTBibl2= MVK0PEBp Mnj6SG1UVw>? MYnpcoR2[2W|IFeyM20h[XK{ZYP0 NYTHS3lQOjRzNES3N|c>
OS-RC-2 M3;u[mFxd3C2b4Ppd{BCe3OjeR?= NEHiVow2OCCwTR?= MnnxOFghcA>? MYPEUXNQ MkHsbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NYLEVGZ7OjRzNES3N|c>
SK-N-AS NGnwWXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXtNQKBmzhyIH7N MoPKOFghcA>? MmP5TWM2OD1{Nz60JI5O MlPsNlQxQTh5OUm=
SK-N-DZ NWHtO|V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPjN5VLOOLCk{iwJI5O MYO0PEBp MWfJR|UxRTJzLkmgcm0> M3HsT|I1ODl6N{m5
SK-N-SH NYKwfmw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXiw5qCUQDBibl2= NIfDTI41QCCq NXfHfWc6UUN3ME23Nk4{KG6P NVjlR5VMOjRyOUi3PVk>
SK-N-BE M330NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf1NQKBmzhyIH7N NHTadFM1QCCq NYryR2h1UUN3ME23OU41KG6P MUmyOFA6QDd7OR?=
SK-N-AS MYDBdI9xfG:|aYOgRZN{[Xl? NGfNWI8x6oDVOECgcm0> NI\rW5o1QCCq NWXDXZhjeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v NIO0S2YzPDB7OEe5PS=>
SK-N-DZ NV2zV|V6SXCxcITvd4l{KEG|c3H5 NE\0dnAx6oDVOECgcm0> MlzsOFghcA>? MXHwc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36= MorHNlQxQTh5OUm=
SK-N-SH MVPBdI9xfG:|aYOgRZN{[Xl? NFvZXm0x6oDVNECgcm0> NYq4UVRsPDhiaB?= NVvmWGNLeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v Moi2NlQxQTh5OUm=
SK-N-BE NGf2VI9CeG:ydH;zbZMhSXO|YYm= NF:zRWIx6oDVNECgcm0> MoDCOFghcA>? MoezdI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u M3LHRlI1ODl6N{m5
SK-N-AS MWHGeY5kfGmxbjDBd5NigQ>? M3zQXlDjiJN6MDDuUS=> NGm4N481QCCq NX7EfoV5cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? NV7GWnc3OjRyOUi3PVk>
SK-N-DZ NYi3flBpTnWwY4Tpc44hSXO|YYm= MWCw5qCUQDBibl2= NHW3PVA1QCCq MlL2bY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> NIPyTpMzPDB7OEe5PS=>
SK-N-SH MXHGeY5kfGmxbjDBd5NigQ>? MXyw5qCUPDBibl2= MXy0PEBp NUix[mc3cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? M1\mXVI1ODl6N{m5
SK-N-BE NVr1NGlDTnWwY4Tpc44hSXO|YYm= MXOw5qCUPDBibl2= MXG0PEBp NUDWXVhEcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? NWnmTnVFOjRyOUi3PVk>
HCC-LM3 NV;VRpROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDLNU0yODByIH7N MUmyOE81QC95MjDo NXjvOI5iTE2VTx?= NV7XcnN{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NXzhUWtnOjRyOUO5OVY>
HepG2 MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TMSVEuOTByMDDuUS=> NXPVRZZzOjRxNEivO|IhcA>? MljJSG1UVw>? MmnMbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MkfONlQxQTN7NU[=
SMMC-7721 M{[2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2flOVEuOTByMDDuUS=> M{DZT|I1NzR6L{eyJIg> MVfEUXNQ NGX1TINqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MX:yOFA6Ozl3Nh?=
HCC-LM3 NFX4ToVCeG:ydH;zbZMhSXO|YYm= M2TSTlUxKG6P NXy5eog2PDhiaB?= MlP0SG1UVw>? MWTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bImgbY4h[SClYYPwZZNmNWSncHXu[IVvfCCvYX7u[ZIh[nliY3zlZZZi\2Vib3[gZ4F{eGG|ZYOgN{whQCCjbnSgPS=> MUKyOFA6Ozl3Nh?=
HepG2 NUDRT4d6SXCxcITvd4l{KEG|c3H5 NYW0XIlyPTBibl2= NXrEZWl1PDhiaB?= M1\KTGROW09? MkXzbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk> M4\ORVI1ODl|OUW2
SMMC-7721 M2HTfGFxd3C2b4Ppd{BCe3OjeR?= NV3lWVVxPTBibl2= MYC0PEBp NV7IU|ZiTE2VTx?= MYnpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bImgbY4h[SClYYPwZZNmNWSncHXu[IVvfCCvYX7u[ZIh[nliY3zlZZZi\2Vib3[gZ4F{eGG|ZYOgN{whQCCjbnSgPS=> NFSwZ5gzPDB7M{m1Oi=>
HCC-LM3 NVe3XY94TnWwY4Tpc44hSXO|YYm= NGfacpM2OC9zMECgcm0> NUHkUGlGOjRiaB?= MkPNSG1UVw>? NUXs[GtT\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> NX\odIdyOjRyOUO5OVY>
HepG2 NEC3R|NHfW6ldHnvckBCe3OjeR?= NF\jPZk2OC9zMECgcm0> NXnnR4RoOjRiaB?= MYfEUXNQ M2HNO4Rm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC= MXWyOFA6Ozl3Nh?=
SMMC-7721 MmXPSpVv[3Srb36gRZN{[Xl? MoiwOVAwOTByIH7N NVvSeVZzOjRiaB?= NWPwVFRVTE2VTx?= NVHDdHho\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> MXWyOFA6Ozl3Nh?=
HCC-LM3 M3HXdmZ2dmO2aX;uJGF{e2G7 MmDqOVAwOTByIH7N MV2yOEBp MV3EUXNQ NH;nOG1ld3ewcnXneYxifGW|IFLjcE15VCCneIDy[ZN{cW:w MYmyOFA6Ozl3Nh?=
HepG2 NFXoVoFHfW6ldHnvckBCe3OjeR?= MnqxOVAwOTByIH7N M1PnN|I1KGh? MlLNSG1UVw>? NFHB[Ylld3ewcnXneYxifGW|IFLjcE15VCCneIDy[ZN{cW:w M1G1cFI1ODl|OUW2
SMMC-7721 NHjqOY1HfW6ldHnvckBCe3OjeR?= NGnXVmM2OC9zMECgcm0> MkTPNlQhcA>? NUH3SYpWTE2VTx?= NHvpTWFld3ewcnXneYxifGW|IFLjcE15VCCneIDy[ZN{cW:w M1n0elI1ODl|OUW2
FaDu MoDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1T4d|ExOOLChX7N NEnhRow5NzFyL{GyJIg> MmjT[Il{eGyjeXXkJIEhe2mpbnnmbYNidnRiYX7kJJBzd2yxbnfl[EBIOi:PIHHydoV{fCCjdDC4JIFv\CBzMvMAiYgheG:|dDDy[Yxm[XOn NXTEfGMxOjRyMk[0PFI>
FaDu M{C1UmZ2dmO2aX;uJGF{e2G7 M2nVR|ExOOLChX7N NYfpS2RXOi92L{ivNVIhcA>? MUTpcoR2[2WmIICyNXdi\jFxQ3nwNeKh\XiycnXzd4lwdg>? NXu1OJd2OjRyMk[0PFI>
PC-3  NGD5RY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlr3NE0yOCEQvF2= MXKyOE81QC95MjDo NH21[W9qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NVPnSmhvOjN7OUGyNVY>
LNCaP M4jq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HPelAuPSEQvF2= MkT6NlQwPDhxN{KgbC=> NXvHRpNxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFz0RlczOzl7MUKxOi=>
RWPE-1  NWn3[Y85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqwMVIxKM7:TR?= MViyOE81QC95MjDo MUPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFz0dWgzOzl7MUKxOi=>
Capan-1 NEG4UJlHfW6ldHnvckBCe3OjeR?= NInze3kzPS93MD:xNFAhdk1? MUW4M|I1NzR6IHi= Mn7kSG1UVw>? NUm3ZlN5\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=> Mmf4NlM6OjJ6OE[=
L3.6pl NHfJPXhHfW6ldHnvckBCe3OjeR?= Mn3MNlUwPTBxMUCwJI5O MV:4M|I1NzR6IHi= NX\hemNiTE2VTx?= MVHkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p NXm5NJBTOjN7MkK4PFY>
CFPAC-1  NFXC[nBHfW6ldHnvckBCe3OjeR?= MnXkNlUwPTBxMUCwJI5O M4fVR|gwOjRxNEigbC=> MofwSG1UVw>? NYHXNGVR\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=> NXzYVGhxOjN7MkK4PFY>
Capan-1 NV65TXVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUe4T4twOjVxNUCvNVAxKG6P MYO0PEBp MXLEUXNQ NWLYe49FemWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MoLKNlM6OjJ6OE[=
L3.6pl MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzrNmozPS93MD:xNFAhdk1? NFq5b5I1QCCq NFjBfWJFVVOR MkDOdoVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MYiyN|kzOjh6Nh?=
CFPAC-1  NYTDbHd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWGyOU82OC9zMECgcm0> NFLMRVU1QCCq MnPRSG1UVw>? NFXofYpz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MluzNlM6OjJ6OE[=
Capan-1 M2D6R2Fxd3C2b4Ppd{BCe3OjeR?= MkLUNlUwPTBxMUCwJI5O M4nGUFQ5KGh? NETKTYVFVVOR M4XYUIlv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnfQNlM6OjJ6OE[=
L3.6pl M4PrdGFxd3C2b4Ppd{BCe3OjeR?= NIjMZ3EzPS93MD:xNFAhdk1? MkDSOFghcA>? M1fP[2ROW09? NX\Hd49icW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MX[yN|kzOjh6Nh?=
CFPAC-1  MVTBdI9xfG:|aYOgRZN{[Xl? MXuyOU82OC9zMECgcm0> MnfJOFghcA>? NUjPS2JyTE2VTx?= MofZbY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NWH6UZc4OjN7MkK4PFY>
HN22 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\6TlAuOjBibl2= MVGyOE81QCCq MYjEUXNQ NHPycGpqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz M{jlU|I{QDd5MkO1
HSC4  MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnzVod4OC1{MDDuUS=> NUXwbFN1OjRxNEigbC=> NHPXdnRFVVOR NVOzOpVncW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? M17aWVI{QDd5MkO1
HN22 Mn\aRZBweHSxc3nzJGF{e2G7 NX7me5Q2OC1{MDDuUS=> NF:xNmY1QCCq NVLPXWczTE2VTx?= M4jjSIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NUXzeo9UOjN6N{eyN|U>
HSC4  MUfBdI9xfG:|aYOgRZN{[Xl? MXewMVIxKG6P M132fFQ5KGh? NED3SHdFVVOR NXLofotXcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NY\SUJh4OjN6N{eyN|U>
HN22 NHfJTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLwZ4oxNTJyIH7N NV3EToFqPDhiaB?= NVfjOmhVTE2VTx?= MVvpcoR2[2W|IFexJJBp[XOnIHPlcIwh[3mlbHWgZZJz\XO2wrC= NHnIcpUzOzh5N{KzOS=>
HSC4  NHqxNIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXmWZN6OC1{MDDuUS=> M1z4[FQ5KGh? NHHrR25FVVOR MWLpcoR2[2W|IFexJJBp[XOnIHPlcIwh[3mlbHWgZZJz\XO2wrC= MWGyN|g4PzJ|NR?=
HN22 M1LwVWZ2dmO2aX;uJGF{e2G7 MVSwMVIxKG6P MkDrOFghcA>? NWPlPII2TE2VTx?= MYTzeZBxemW|c3XzJHNxOSCneIDy[ZN{cW:wwrC= MljLNlM5Pzd{M{W=
HSC4  M1jTfWZ2dmO2aX;uJGF{e2G7 NHjs[JAxNTJyIH7N MlS2OFghcA>? M4r4VmROW09? NX\VPZl2e3WycILld5NmeyCVcEGg[ZhxemW|c3nvcuKh MoP1NlM5Pzd{M{W=
Cal62 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmW1TWM2OD1|MzFCtUA1KG6P MmHuNlM5OjRyNkS=
Hth7 M4iwNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPLNG1KSzVyPUG1JOKyKDJibl2= MYGyN|gzPDB4NB?=
Hth83 M{n4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TBWmlEPTB;M{SgxtEhPSCwTR?= M2PzTVI{QDJ2ME[0
C643 MnHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTdzINMxJFExKG6P M1PmSVI{QDJ2ME[0
SW1736 MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTN3INMxJFghdk1? MWCyN|gzPDB4NB?=
T241 NGDIdoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTZ3INMxJFchdk1? NHLzXmgzOzh{NEC2OC=>
T351 MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof5TWM2OD13MDFCtUAyOCCwTR?= NGS3NoczOzh{NEC2OC=>
BHP2-7 NV:0[4NOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljoTWM2OD1|NzFCtUA3KG6P NXr3bW5wOjN6MkSwOlQ>
T238 NV:zfW5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rLT2lEPTB;MTy1NFAhyrFiMkCwJI5O NEjZe2IzOzh{NEC2OC=>
HCT8 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS4PZQ4OiCq MnjESG1UVw>? NIjpdVBKSzVyPUGyMlnjiIoEsfMAjVEvQSCwTR?= MWSyN|I6QTN6OB?=
H630 NFzwRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XwVVczKGh? Ml\4SG1UVw>? MVHJR|UxRTF{LkVihKnDueLCiUOuNUBvVQ>? MV:yN|I6QTN6OB?=
cH630 5-FU-res NHvFPG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVO3NkBp MX;EUXNQ M{DiSWlEPTB;MUWuOgKBkcLz4pEJNU4zKG6P NXj2cm1tOjN{OUmzPFg>
HCT116 NGPZOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\3W3g4OiCq Ml2xSG1UVw>? NHn0cI1KSzVyPUGwMlfjiIoEsfMAjVIvOiCwTR?= MmT4NlMzQTl|OEi=
HCT116 p53−/− NWW2dZV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fielczKGh? M3njTWROW09? MkG0TWM2OD16LkdihKnDueLCiUGuO{BvVQ>? MVmyN|I6QTN6OB?=
dHCT116 p21−/− NEjRWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXe3NkBp MoDMSG1UVw>? NUiyc4hRUUN3ME21MlnjiIoEsfMAjVEvOyCwTR?= MkD4NlMzQTl|OEi=
HT29 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nRSVczKGh? NVHoWVJ5TE2VTx?= NYXQWFV1UUN3ME2xOk4{6oDLwsJihKkzNjNibl2= MXyyN|I6QTN6OB?=
LoVo M2\aUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLsc21nPzJiaB?= NVLMXJQ5TE2VTx?= MULJR|UxRTVwMfMAjeKy6oDLMD62JI5O M{ntVFI{Ojl7M{i4
RKO NGH1VHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTYO|IhcA>? NUfR[IF6TE2VTx?= Ml;nTWM2OD15LkpihKnDueLCiUKuNkBvVQ>? MXWyN|I6QTN6OB?=
SW480 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml75O|IhcA>? MkWwSG1UVw>? MULJR|UxRTF5LkZihKnDueLCiUCuPEBvVQ>? NYHU[ZZxOjN{OUmzPFg>
eSW620 Mor1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPnO|IhcA>? NWXNeYV{TE2VTx?= NV2yboxMUUN3ME25MlHjiIoEsfMAjVIvOSCwTR?= MkSzNlMzQTl|OEi=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
DNMT1 / EZH2; 

PubMed: 19279403     


Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control.

caspase-8 / cleaved caspase-8 / Sp1; 

PubMed: 27738323     


The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. 

c-Myc / IRF4; 

PubMed: 27738323     


RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting.

Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; 

PubMed: 28915627     


Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1.

RAD51 / BRCA1 / CHK1 / RPL13a; 

PubMed: 24244429     


CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells.

H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; 

PubMed: 31071955     


Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.

19279403 27738323 28915627 24244429 31071955
Immunofluorescence
Synaptophysin / NACM; 

PubMed: 28915627     


Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm.

α-tubulin / Acetyl-α-tubulin; 

PubMed: 29983882     


CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm.

BiP; 

PubMed: 23544167     


Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

ATF4; 

PubMed: 23544167     


HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

IRE1α / S724-IRE1α; 

PubMed: 23544167     


Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

28915627 29983882 23544167
Growth inhibition assay
Cell viability; 

PubMed: 27738323     


The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.

27738323
体内試験 In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

お薦めの試験操作(参考用のみ)

細胞試験: [1]
- 合併
  • 細胞株: MOLT-4 cell lines and Reh (pre-B cells)
  • 濃度: 50 nM
  • 反応時間: 48 hours
  • 実験の流れ: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (参考用のみ)
動物試験:[2]
- 合併
  • 動物モデル: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • 投薬量: 10 mg/kg, 20 mg/kg
  • 投与方法: Administered via i.p. injection
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 349.43
化学式

C21H23N3O2

CAS No. 404950-80-7
Storage powder
in solvent
別名 NVP-LBH589
Smiles CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=C([NH]1)C=CC=C3

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04341311 Not yet recruiting Drug: Marizomib|Drug: Panobinostat Diffuse Intrinsic Pontine Glioma|Pediatric Brainstem Glioma|Pediatric Brainstem Gliosarcoma Recurrent|Pediatric Cancer|Pediatric Brain Tumor|Diffuse Glioma Dana-Farber Cancer Institute|Celgene|Secura Bio May 2020 Phase 1
NCT03632317 Withdrawn Drug: Panobinostat|Drug: Everolimus Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center October 2019 Phase 2
NCT03982134 Withdrawn Drug: PDR001|Drug: Panobinostat Melanoma|Non Small Cell Lung Cancer Muhammad Furqan|Novartis Pharmaceuticals|University of Iowa September 2019 Phase 1
NCT04326764 Recruiting Drug: Panobinostat Acute Myeloid Leukaemia (AML)|Myelodysplastic Syndromes (MDS) Goethe University|Jan J. Cornelissen (HOVON-SAKK)|Sebastian Giebel (PALG) July 24 2018 Phase 3
NCT03515915 Unknown status -- Patients With Recurrent or Refractory Multiple Myeloma University Hospital Montpellier|Poitiers University Hospital April 23 2018 --

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    How to reconstitute the compound for in vivo mice study?

  • 回答:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Panobinostat (LBH589)を買う | Panobinostat (LBH589) ic50 | Panobinostat (LBH589)供給者 | Panobinostat (LBH589)を購入する | Panobinostat (LBH589)費用 | Panobinostat (LBH589)生産者 | オーダーPanobinostat (LBH589) | Panobinostat (LBH589)化学構造 | Panobinostat (LBH589)分子量 | Panobinostat (LBH589)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID